OncoSil Medical (ASX: OSL) has received approval from the Australian Therapeutic Goods Administration (TGA) for its OncoSil Class III medical device.
The approval is for the treatment of unresectable locally advanced pancreatic cancer when used in addition to gemcitabine-based chemotherapy.
The device has been officially included on the Australian Register of Therapeutic Goods, which enables its commercialisation within Australia.
The company highlights that Australia records 4,353 new pancreatic cancer cases annually, positioning this approval as a pathway to broader clinical adoption.
Management links scaling commercialisation efforts to the near-completion of a new manufacturing facility located in Macquarie Park that is being developed in partnership with Cyclotek.
This new facility is designed to strengthen OncoSil Medical's supply capabilities as the company expands its commercial operations.
Financial and Corporate Update
In its 1H FY26 update, OncoSil Medical reported record dose sales and cash receipts, alongside several European commercial milestones and clinical and regulatory progress.
The company also completed its first radioactive production run at its Sydney facility and received an $1.84 million R&D tax incentive refund.
An approximately $8.0 million capital raise was executed in February 2026 to fund ongoing commercial expansion.
CEO Nigel Lange agreed to a 10% reduction in his fixed remuneration, effective 1 February 2026, with the foregone cash amount to be replaced by ordinary shares issued at $1.50 per share.
This equity-linked remuneration aims to align management interests with shareholders and reduce immediate cash costs. This arrangement remains subject to shareholder approval.
Outlook for OncoSil Medical
The TGA approval represents a crucial commercial gateway for OncoSil Medical in Australia.
While regulatory hurdles have been cleared, the company's success hinges on effective commercial execution, scaling manufacturing, and continued clinical validation.
It must also manage its significant operating cash burn and ensure ongoing regulatory compliance.
